Shots:
BI & Cue Biopharma have entered into a multi-year strategic research & license agreement to develop & commercialize CUE-501 for autoimmune diseases, with the potential to expand into other B cell-targeting bispecifics using Cue’s Immuno-STAT platform
As per the deal, Cue Biopharma will receive a $12M upfront & ~$345M in research, development, & commercial…
